NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.18 +0.07 (+3.32 %) (As of 01/23/2019 12:42 PM ET)Previous Close$2.11Today's Range$2.11 - $2.2752-Week Range$1.29 - $4.34Volume603,859 shsAverage Volume2.57 million shsMarket Capitalization$302.19 millionP/E Ratio-3.52Dividend YieldN/ABeta2.11 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut. Receive ACHN News and Ratings via Email Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACHN Previous Symbol CUSIP00448Q20 Webwww.achillion.com Phone203-624-7000Debt Debt-to-Equity RatioN/A Current Ratio33.23 Quick Ratio33.23Price-To-Earnings Trailing P/E Ratio-3.52 Forward P/E Ratio-4.19 P/E GrowthN/A Sales & Book Value Annual Sales$15 million Price / Sales20.15 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book0.93Profitability EPS (Most Recent Fiscal Year)($0.62) Net Income$-85,230,000.00 Net MarginsN/A Return on Equity-25.48% Return on Assets-24.70%Miscellaneous Employees88 Outstanding Shares138,620,000Market Cap$302.19 million OptionableOptionable Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions What is Achillion Pharmaceuticals' stock symbol? Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN." How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. View Achillion Pharmaceuticals' Earnings History. When is Achillion Pharmaceuticals' next earnings date? Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Achillion Pharmaceuticals. What price target have analysts set for ACHN? 2 brokerages have issued twelve-month target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $3.50 to $5.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $4.25 in the next year. This suggests a possible upside of 95.0% from the stock's current price. View Analyst Price Targets for Achillion Pharmaceuticals. What is the consensus analysts' recommendation for Achillion Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals. Has Achillion Pharmaceuticals been receiving favorable news coverage? Headlines about ACHN stock have been trending somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. Are investors shorting Achillion Pharmaceuticals? Achillion Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 7,425,448 shares, an increase of 42.0% from the December 14th total of 5,230,507 shares. Based on an average trading volume of 5,878,756 shares, the days-to-cover ratio is currently 1.3 days. Currently, 5.5% of the company's shares are short sold. View Achillion Pharmaceuticals' Current Options Chain. Who are some of Achillion Pharmaceuticals' key competitors? Some companies that are related to Achillion Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Uniqure (QURE), Spectrum Pharmaceuticals (SPPI), Esperion Therapeutics (ESPR), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Retrophin (RTRX), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX) and Athenex (ATNX). Who are Achillion Pharmaceuticals' key executives? Achillion Pharmaceuticals' management team includes the folowing people: Mr. Joseph Truitt, Pres, CEO & Director (Age 54)Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)Ms. Keri Lantz, Interim Principal Financial Officer, Principal Accounting Officer, Controller & VP of Fin. (Age 44)Mr. Paul Firuta, Exec. VP & COO (Age 53)Mr. Brian R. DiDonato, VP of Investor Relations & Corp. Communications (Age 52) Who are Achillion Pharmaceuticals' major shareholders? Achillion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bourgeon Capital Management LLC (0.02%) and Meeder Asset Management Inc. (0.02%). View Institutional Ownership Trends for Achillion Pharmaceuticals. Which major investors are selling Achillion Pharmaceuticals stock? ACHN stock was sold by a variety of institutional investors in the last quarter, including Bourgeon Capital Management LLC. View Insider Buying and Selling for Achillion Pharmaceuticals. Which major investors are buying Achillion Pharmaceuticals stock? ACHN stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. View Insider Buying and Selling for Achillion Pharmaceuticals. How do I buy shares of Achillion Pharmaceuticals? Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Achillion Pharmaceuticals' stock price today? One share of ACHN stock can currently be purchased for approximately $2.18. How big of a company is Achillion Pharmaceuticals? Achillion Pharmaceuticals has a market capitalization of $302.19 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe. What is Achillion Pharmaceuticals' official website? The official website for Achillion Pharmaceuticals is http://www.achillion.com. How can I contact Achillion Pharmaceuticals? Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000. MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 430 (Vote Outperform)Underperform Votes: 344 (Vote Underperform)Total Votes: 774MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: Why does a company issue an IPO?